Rachel E. Hodgson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rachel E. Hodgson has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Anna Sanchez Avila
Sheffield Institute for Translational Neuroscience (SITraN) and Neuroscience Institute, University of Sheffield, Sheffield, UK
1 shared publicationBrittany C. S. Ellis
Sheffield Institute for Translational Neuroscience (SITraN) and Neuroscience Institute, University of Sheffield, Sheffield, UK
1 shared publication- Emily Day
University of Oxford Department of Biology South Parks Road, Oxford OX1 3RB
1 shared publication - Eugene V. Makeyev
Centre for Developmental Neurobiology, King's College London, London SE1 1UL, UK
1 shared publication - Haiyan An
Medical School, Swansea University, Swansea, UK
1 shared publication - Jenny Lord
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK
1 shared publication
Latest Publications
- Open Access
- 25 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (30) , eadx1357
M6A-dependent RNA condensation underlies FUS autoregulation and can be harnessed for ALS therapy development
Mutations in the FUS gene cause aggressive amyotrophic lateral sclerosis (ALS-FUS). Beyond mRNA, FUS generates partially processed transcripts retaining introns 6 and 7. We demonstrate that these FUSint6&7-RNA molecules form nuclear condensates, scaffolded by the highly structured intron 7 and associated with nuclear speckles. Using hybridization-proximity labeling proteomics, we show that the FUSint6&7-RNA condensates are enriched for splicing factors and the N6-methyladenosine (m6A) reader YTHDC1. These ribonucleoprotein structures facilitate posttranscriptional FUS splicing and depend on m6A/YTHDC1 for integrity. In cells expressing mutant FUS, FUSint6&7-RNAs become hypermethylated, which in turn stimulates their condensation and splicing. We further show that FUS protein is repelled by m6A. Thus, ALS-FUS mutations may cause abnormal activation of FUS posttranscriptional splicing through altered RNA methylation. Notably, ectopic expression of FUS intron 7 sequences dissolves endogenous FUSint6&7-RNA condensates, down-regulating FUS mRNA and protein. Our findings reveal a condensation-dependent mechanism regulating FUS splicing, with possible therapeutic implications for ALS.
- 25 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (30) , eadx1357
Open AccessM6A-dependent RNA condensation underlies FUS autoregulation and can be harnessed for ALS therapy development
Mutations in the FUS gene cause aggressive amyotrophic lateral sclerosis (ALS-FUS). Beyond mRNA, FUS generates partially processed transcripts retaining introns 6 and 7. We demonstrate that these FUSint6&7-RNA molecules form nuclear condensates, scaffolded by the highly structured intron 7 and associated with nuclear speckles. Using hybridization-proximity labeling proteomics, we show that the FUSint6&7-RNA condensates are enriched for splicing factors and the N6-methyladenosine (m6A) reader YTHDC1. These ribonucleoprotein structures facilitate posttranscriptional FUS splicing and depend on m6A/YTHDC1 for integrity. In cells expressing mutant FUS, FUSint6&7-RNAs become hypermethylated, which in turn stimulates their condensation and splicing. We further show that FUS protein is repelled by m6A. Thus, ALS-FUS mutations may cause abnormal activation of FUS posttranscriptional splicing through altered RNA methylation. Notably, ectopic expression of FUS intron 7 sequences dissolves endogenous FUSint6&7-RNA condensates, down-regulating FUS mRNA and protein. Our findings reveal a condensation-dependent mechanism regulating FUS splicing, with possible therapeutic implications for ALS.